Bruce Weintraub

President and CEO, Trophogen

Dr. Weintraub has more than 30 years experience in a biomedical research career that has focused on molecular, cellular, clinical and therapeutic aspects of glycoprotein hormones, related growth factors, thyroid hormone and their receptors. He is the author of over 300 scientific papers, reviews and book chapters. In addition has several issued and pending patents related to the cloning of the human TSH beta subunit, development of recombinant TSH, and development of superactive analogs of TSH, gonadotropins and related cystine knot growth factors.

He is well known for his basic science work related to pituitary and recombinant TSH synthesis, glycosylation and action, affinity chromatography as well as clinical aspects of syndromes of inappropriate TSH secretion. In addition he was among the first to recognize and define the clinical and molecular aspects of thyroid hormone resistance, TSH- producing pituitary tumors and ectopic production of placental hormones and free subunits by various tumors. He is particularly recognized for his role as coinventor, codeveloper and a leading investigator in the international clinical trials of recombinant TSH, approved by the FDA in 1998 for the diagnosis of thyroid cancer, which has revolutionized the approach world -wide to that disease.